|
1
|
Lassman AB and DeAngelis LM: Brain
metastases. Neurol Clin. 21:1–23, vii. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stark AM: Neurosurgical treatment of
breast cancer metastases to the neurocranium. Patholog Res Int.
2011:5498472010.PubMed/NCBI
|
|
3
|
Sihto H, Lundin J, Lundin M, Lehtimäki T,
Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T,
Isola J, et al: Breast cancer biological subtypes and protein
expression predict for the preferential distant metastasis sites: A
nationwide cohort study. Breast Cancer Res. 13:R872011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weil RJ, Palmieri DC, Bronder JL, Stark AM
and Steeg PS: Breast cancer metastasis to the central nervous
system. Am J Pathol. 167:913–920. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heitz F, Rochon J, Harter P, Lueck HJ,
Fisseler-Eckhoff A, Barinoff J, Traut A, Lorenz-Salehi F and du
Bois A: Cerebral metastases in metastatic breast cancer:
Disease-specific risk factors and survival. Ann Oncol.
22:1571–1581. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miller KD, Weathers T, Haney LG, Timmerman
R, Dickler M, Shen J and Sledge GW Jr: Occult central nervous
system involvement in patients with metastatic breast cancer:
Prevalence, predictive factors and impact on overall survival. Ann
Oncol. 14:1072–1077. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heitz F, Harter P, Lueck HJ,
Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A and
du Bois A: Triple-negative and HER2-overexpressing breast cancers
exhibit an elevated risk and an earlier occurrence of cerebral
metastases. Eur J Cancer. 45:2792–2798. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pestalozzi BC, Zahrieh D, Price KN,
Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E,
Pagani O, et al: Identifying breast cancer patients at risk for
central nervous system (CNS) metastases in trials of the
international breast cancer study group (IBCSG). Ann Oncol.
17:935–944. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Niikura N, Saji S, Tokuda Y and Iwata H:
Brain metastases in breast cancer. Jpn J Clin Oncol. 44:1133–1140.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
DiStefano A, Yap Y Yong, Hortobagyi GN and
Blumenschein GR: The natural history of breast cancer patients with
brain metastases. Cancer. 44:1913–1918. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsukada Y, Fouad A, Pickren JW and Lane
WW: Central nervous system metastasis from breast carcinoma.
Autopsy study. Cancer. 52:2349–2354. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng X and Hung MC: Breast cancer brain
metastases. Cancer Metastasis Rec. 26:635–643. 2007. View Article : Google Scholar
|
|
13
|
Leone JP and Leone BA: Breast cancer brain
metastases: The last frontier. Exp Hematol Oncol. 4:332015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kennecke H, Yerushalmi R, Woods R, Cheang
MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic
behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Palmieri D, Bronder JL, Herring JM, Yoneda
T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L,
Halverson D, et al: Her-2 overexpression increases the metastatic
outgrowth of breast cancer cells in the brain. Cancer Res.
67:4190–4198. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American society of
clinical oncology/college of American pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hammond ME, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,
Hayes M, et al: American society of clinical oncology/college of
American pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Blows FM, Driver KE, Schmidt MK, Broeks A,
van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO,
Blomqvist C, et al: Subtyping of breast cancer by
immunohistochemistry to investigate a relationship between subtype
and short and long term survival: A collaborative analysis of data
for 10,159 cases from 12 studies. PLoS Med. 7:e10002792010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rostami R, Mittal S, Rostami P, Tavassoli
F and Jabbari B: Brain metastasis in breast cancer: A comprehensive
literature review. J Neurooncol. 127:407–414. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Berghoff A, Bago-Horvath Z, De Vries C,
Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H,
Fitzal F, et al: Brain metastases free survival differs between
breast cancer subtypes. Br J Cancer. 106:440–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Anders CK, Deal AM, Miller CR, Khorram C,
Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM and
Carey LA: The prognostic contribution of clinical breast cancer
subtype, age and race among patients with breast cancer brain
metastases. Cancer. 117:1602–1611. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nam BH, Kim SY, Han HS, Kwon Y, Lee KS,
Kim TH and Ro J: Breast cancer subtypes and survival in patients
with brain metastases. Breast Cancer Res. 10:R202008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Niwińska A, Murawska M and Pogoda K:
Breast cancer brain metastases: Differences in survival depending
on biological subtype, RPA RTOG prognostic class and systemic
treatment after whole-brain radiotherapy (WBRT). Ann Oncol.
21:942–948. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park YH, Park MJ, Ji SH, Yi SY, Lim DH,
Nam DH, Lee JI, Park W, Choi DH and Huh SJ: Trastuzumab treatment
improves brain metastasis outcomes through control and durable
prolongation of systemic extracranial disease in
HER2-overexpressing breast cancer patients. Br J Cancer.
100:894–900. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Panel members: Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the St Gallen international expert consensus on the primary therapy
of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Perez EA, Romond EH, Suman VJ, Jeong JH,
Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA and
Wolmark N: Four-year follow-up of trastuzumab plus adjuvant
chemotherapy for operable human epidermal growth factor receptor
2-positive breast cancer: Joint analysis of data from NCCTG N9831
and NSABP B-31. J Clin Oncol. 29:3366–3373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vaz-Luis I, Ottesen RA, Hughes ME, Marcom
PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC and
Lin NU: Impact of hormone receptor status on patterns of recurrence
and clinical outcomes among patients with human epidermal growth
factor-2-positive breast cancer in the national comprehensive
cancer network: A prospective cohort study. Breast Cancer Res.
14:R1292012. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wasielewski Rv, Hasselmann S, Rüschoff J,
Fisseler-Eckhoff A and Kreipe H: Proficiency testing of
immunohistochemical biomarker assays in breast cancer. Virchows
Arch. 453:537–543. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yao H, He G, Yan S, Chen C, Song L, Rosol
TJ and Deng X: Triple-negative breast cancer: Is there a treatment
on the horizon? Oncotarget. Sep 27–2016.(Epub ahead of print). doi:
10.18632/oncotarget.1.2284.
|
|
30
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours, UICC, International
Union against Cancer. 7th. Wiley-Blackwell; 2010
|
